Hepatocellular Carcinoma Pipeline Drugs Report 2025: Exploring Novel Mechanisms of Action, Ongoing Clinical Trials, Pharma Collaborations, and the Future Outlook

DelveInsight's "Hepatocellular Carcinoma Pipeline Insight 2025" report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in the Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Hepatocellular Carcinoma Treatment Landscape. Click here to read more @ Hepatocellular Carcinoma Pipeline Outlook [https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Hepatocellular Carcinoma Pipeline Report

* On 17 September 2025, AstraZeneca announced a Phase I/II study will evaluate the safety, tolerability, antitumour activity, cellular kinetics, pharmacodynamics, and immunogenicity of AZD5851 in adult participants with GPC3+ advanced/recurrent HCC, where at least one line of prior therapy has failed/or was intolerable, or participant/investigator decision.
* DelveInsight's Hepatocellular Carcinoma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for Hepatocellular Carcinoma treatment.
* The leading Hepatocellular Carcinoma Companies such as Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics , and others
* Promising Hepatocellular Carcinoma Therapies such as Pembrolizumab, Tislelizumab, HLX53 (1000mg), Atezolizumab, Bevacizumab, Tiragolumab, Nivolumab and others

Discover groundbreaking developments in Hepatocellular Carcinoma therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Hepatocellular Carcinoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Hepatocellular Carcinoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Hepatocellular Carcinoma Pipeline Report also highlights the unmet needs with respect to the Hepatocellular Carcinoma.

Hepatocellular Carcinoma Overview

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Hepatocellular carcinoma occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection. Cirrhosis is a significant step in viral carcinogenesis for hepatocellular carcinoma. Integration of the hepatitis B virus genome into the host genome is the primary pathogenesis for oncogenesis in HBV. Insertion of viral genome in telomerase reverse transcriptase (TERT) promoter sites of the human genome resulting in mutation accounting for 60% of HCC cases. Other genetic alterations include mutations in TP53 (affecting cell cycle), beta-1 catenin (CTNNBI), axis inhibitor-1 (AXINI), AT-rich interaction domain-containing protein 1A (ARID1A), and ARID2(chromatin proliferation).

Hepatocellular Carcinoma Emerging Drugs

- Namodenoson: Can-Fite BioPharma

Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5'- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). The drug had been out-licensed to Chong Kun Dang (CKD) Pharmaceutical in Korea and to CMS in China.for the treatment of Hepatocellular Carcinoma and NASH. A Phase I/II study in hepatocellular carcinoma (HCC) successfully met its primary and secondary endpoints demonstrating initial indications for efficacy of Namodenoson. A global Phase II study treating patients with Namodenoson as a second-line therapy has recently been concluded.

- SRF388: Surface Oncology

SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine. IL-27 is an immunosuppressive cytokine involved in resolving T cell mediated inflammation. Recent data points to IL-27 as a master regulator of the expression of co-inhibitory receptors expressed on CD4+ and CD8+ T cells. Elevated levels of IL-27 transcripts and mRNA gene signatures are found in cancer and are associated with poor prognoses. Surface Oncology has identified particular tumor types where IL-27 appears to play an important role in the immunosuppressive tumor microenvironment and may contribute to resistance to treatment with checkpoint inhibitors.

- Porustobart: Harbour BioMed

Porustobart (HBM4003) is a fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from mice. By enhancing antibody-dependent cell cytotoxicity (ADCC) killing activity, porustobart has demonstrated significantly improved depletion specific to high CTLA-4 Treg cells in tumor tissues. The potent anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug in monotherapy and combo-therapy.

- Fisogatinib: CStone Pharmaceuticals

Fisogatinib is an orally available, potent, irreversible inhibitor of FGFR4. Fisogatinib was specifically designed to inhibit FGFR4 with exquisite selectivity, thereby sparing the paralogs FGFR1, FGFR2 and FGFR3 and preventing potential adverse effects. Preclinical data has validated FGFR4 as an oncogenic driver for a subset of patients with advanced HCC. The US Food and Drug Administration has granted orphan drug designation to fisogatinib for the treatment of HCC. Fisogatinib is being investigated in the Phase I/II stage of its development for the treatment of patients with FGFR4-activated HCC.

- STP705: Sirnaomics

STP705 is composed of two siRNA oligonucleotides targeting TGF-1 and COX-2 mRNA respectively and formulated in nanoparticles with a proprietary Histidine-Lysine Co-Polymer (HKP) peptide. Each individual siRNA has demonstrated the ability to inhibit the expression of their target mRNA and combining the two siRNAs produces a synergistic effect that diminishes pro-fibrogenic, pro-inflammatory, and pro-tumorigenic factors. Sirnaomics has completed several pre-clinical studies that demonstrate that inhibition of TGF-1 and COX-2 and is expected to result in the inhibition of tumor growth and provide an alternative approach for the treatment of various Hepatocellular Carcinomas. Molecular analyses of the effects of administering the combination demonstrated that the inhibition of these targets had effects on downstream gene products associated with numerous oncology targets.

Stay informed about the Hepatocellular Carcinoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Hepatocellular Carcinoma Unmet Needs [https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Hepatocellular Carcinoma Pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Hepatocellular Carcinoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatocellular Carcinoma Treatment.
* Hepatocellular Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Hepatocellular Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatocellular Carcinoma market.

Hepatocellular Carcinoma Companies

Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics , and others.

Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

- Oral

- Intravenous

- Subcutaneous

- Parenteral

- Topical

Hepatocellular Carcinoma Products have been categorized under various Molecule types such as

- Recombinant fusion proteins

- Small molecule

- Monoclonal antibody

- Peptide

- Polymer

- Gene therapy

Transform your understanding of the Hepatocellular Carcinoma Pipeline! See the latest progress in drug development and clinical research @ Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Hepatocellular Carcinoma Pipeline Report

* Coverage- Global
* Hepatocellular Carcinoma Companies- Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics , and others
* Hepatocellular Carcinoma Therapies- Pembrolizumab, Tislelizumab, HLX53 (1000mg), Atezolizumab, Bevacizumab, Tiragolumab, Nivolumab and others
* Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Oncology Research-Access the Full Hepatocellular Carcinoma Pipeline Analysis Today! @ Hepatocellular Carcinoma Drugs and Companies [https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Introduction

2. Executive Summary

3. Hepatocellular Carcinoma: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Hepatocellular Carcinoma- DelveInsight's Analytical Perspective

7. Late Stage Products (Phase III)

8. Namodenoson: Can-Fite BioPharma

9. Drug profiles in the detailed report.....

10. Mid Stage Products (Phase II)

11. SRF388: Surface Oncology

12. Drug profiles in the detailed report.....

13. Early Stage Products (Phase I)

14. STP705: Sirnaomics

15. Drug profiles in the detailed report.....

16. Preclinical and Discovery Stage Products

17. Drug name: Company name

18. Drug profiles in the detailed report.....

19. Inactive Products

20. Hepatocellular Carcinoma Key Companies

21. Hepatocellular Carcinoma Key Products

22. Hepatocellular Carcinoma- Unmet Needs

23. Hepatocellular Carcinoma- Market Drivers and Barriers

24. Hepatocellular Carcinoma- Future Perspectives and Conclusion

25. Hepatocellular Carcinoma Analyst Views

26. Hepatocellular Carcinoma Key Companies

27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hepatocellular-carcinoma-pipeline-drugs-report-2025-exploring-novel-mechanisms-of-action-ongoing-clinical-trials-pharma-collaborations-and-the-future-outlook]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hepatocellular-carcinoma-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.